Moderna (MEX:MRNA) Construction In Progress: MXN4,833 Mil (As of Mar. 2026)


MEX:MRNA Moderna Inc MEX:MRNA
59 GF Score
Price MXN1,240.69
GF Value MXN406.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Moderna Construction In Progress?

Moderna MEX:MRNA +2.75% 59 Construction In Progress is MXN4,833 Mil as of Mar. 2026. GuruFocus rates MEX:MRNA with a GF Score™ of 59/100 and a GF Value™ of MXN406.24 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Moderna's quarterly construction in progress declined from Sep. 2025 (MXN6,420 Mil) to Dec. 2025 (MXN5,366 Mil) and declined from Dec. 2025 (MXN5,366 Mil) to Mar. 2026 (MXN4,833 Mil).

Moderna's annual construction in progress increased from Dec. 2023 (MXN14,598 Mil) to Dec. 2024 (MXN22,044 Mil) but then declined from Dec. 2024 (MXN22,044 Mil) to Dec. 2025 (MXN5,366 Mil).

Moderna Construction In Progress Historical Data

* Premium members only.

The historical data trend for Moderna's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moderna Construction In Progress Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,348.97 5,478.38 14,597.85 22,044.48 5,365.70

Moderna Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22,053.94 17,191.06 6,420.47 5,365.70 4,832.76
MEX:MRNA
59GF Score
Moderna Inc MEX:MRNA
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moderna Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of MXN4,833 Mil mean?
Moderna (MEX:MRNA) has a Construction In Progress of MXN4,833 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Moderna and its competitors.
Is Moderna's Construction In Progress too high?
Moderna's current Construction In Progress is MXN4,833 Mil. Overall, Moderna has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Moderna's Construction In Progress compare to RPRX and ROIV?
Moderna's Construction In Progress of MXN4,833 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Moderna and its competitors. Moderna's current Construction In Progress is MXN4,833 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Based on GuruFocus' analysis, Moderna (MEX:MRNA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN406.24, compared to a current price of MXN1,240.69 — trading 205.4% above its estimated fair value. The current Construction In Progress is MXN4,833 Mil. Moderna's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Moderna (MEX:MRNA), the current Construction In Progress is MXN4,833 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moderna (MEX:MRNA) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of MXN1,240.69 is trading 205.4% above its estimated GF Value™ of MXN406.24. GuruFocus considers Moderna to be Significantly Overvalued.

Key valuation signals for MEX:MRNA:

  • Construction In Progress: MXN4,833 Mil
  • GF Value™: MXN406.24 vs. price of MXN1,240.69 (205.4% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the MEX:MRNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
59GF Score

Get the complete analysis for MEX:MRNA

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,240.69
Price
MXN406.24
GF Value